Omeros’ (OMER) “Neutral” Rating Reiterated at Cantor Fitzgerald

Omeros (NASDAQ:OMER)‘s stock had its “neutral” rating restated by Cantor Fitzgerald in a research note issued to investors on Thursday,Benzinga reports.

Several other equities research analysts have also issued reports on the company. Rodman & Renshaw began coverage on Omeros in a research note on Thursday. They issued a “buy” rating and a $9.00 price objective for the company. StockNews.com lowered shares of Omeros from a “hold” rating to a “sell” rating in a report on Tuesday. Finally, Needham & Company LLC reiterated a “hold” rating on shares of Omeros in a report on Thursday.

Omeros Stock Up 28.4 %

NASDAQ:OMER traded up $1.19 on Thursday, reaching $5.38. 483,938 shares of the company’s stock traded hands, compared to its average volume of 396,456. Omeros has a 12 month low of $1.38 and a 12 month high of $5.68. The stock has a 50-day simple moving average of $4.02 and a 200-day simple moving average of $4.05. The firm has a market cap of $311.77 million, a PE ratio of -2.23 and a beta of 1.47.

Institutional Trading of Omeros

Several large investors have recently made changes to their positions in OMER. BNP Paribas Financial Markets boosted its position in Omeros by 130.6% during the third quarter. BNP Paribas Financial Markets now owns 12,388 shares of the biopharmaceutical company’s stock worth $49,000 after acquiring an additional 7,016 shares during the last quarter. SPC Financial Inc. acquired a new position in shares of Omeros during the 3rd quarter worth approximately $77,000. SG Americas Securities LLC purchased a new stake in shares of Omeros in the third quarter valued at approximately $80,000. Oppenheimer & Co. Inc. acquired a new stake in shares of Omeros in the first quarter valued at approximately $85,000. Finally, Comerica Bank lifted its position in Omeros by 20.0% during the first quarter. Comerica Bank now owns 30,000 shares of the biopharmaceutical company’s stock worth $104,000 after buying an additional 5,000 shares in the last quarter. 48.79% of the stock is currently owned by hedge funds and other institutional investors.

About Omeros

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.